In patient #5, splenomegaly and symptoms improved, but thrombocytosis and JAK2 V617F VAF remained unaffected on 30 mg total daily dose of ruxolitinib, which was therefore increased to 40 mg daily. Here, JAK2 is linked to Thrombocytosis.